Merck Profit Margin 2006-2018 | MRK

Current and historical gross margin, operating margin and net profit margin for Merck (MRK) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Merck net profit margin as of June 30, 2018 is 3.67%.
Merck Annual Profit Margins
Merck Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $193.640B $40.122B
Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they work with customers and operate the countries to deliver innovative health solutions. The Company also demonstrate their commitment to increasing access to health care through far-reaching policies, programs and partnerships. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $374.158B 17.54
Pfizer (PFE) United States $265.319B 15.53
Novartis AG (NVS) Switzerland $197.633B 16.95
AbbVie (ABBV) United States $139.722B 13.65
Eli Lilly (LLY) United States $121.994B 22.58
Sanofi (SNY) France $112.061B 14.18
Novo Nordisk (NVO) Denmark $106.293B 16.99
AstraZeneca (AZN) United Kingdom $99.517B 10.94
GlaxoSmithKline (GSK) United Kingdom $98.553B 13.16
Bristol-Myers Squibb (BMY) United States $96.274B 17.43